Published: March 28, 2022

Dear @[email protected],

Your healthcare team has discussed the following subject with you: Natalizumab. The brand name is Tysabri. Here is some additional information. Let us know if you have any questions regarding this information.

  • This medication belongs to a class of drugs called biologics. It helps to reduce irritation and swelling (inflammation) in the intestines. In some cases, this medication is used by itself. In other cases, this medication is used together with another medication to achieve better results.

  • This medication is also considered an integrin receptor antagonist.

  • It is injected into a vein in a procedure called an infusion. The infusion is given at a certified infusion center and lasts approximately 1 hour.

  • Your healthcare team may adjust the dose and how often you receive it, but typically it is given once every 4 weeks.

  • Side effects can include urinary tract infections, upper respiratory infections, headache, tiredness, depression, joint paint, diarrhea, and stomach pain.

  • It carries an increased risk of a severe brain condition called progressive multifocal leukoencephalopathy (PML), which can be caused by the John Cunningham (JC) virus. It is important to be tested for JC virus prior to starting this medication. Patients who are negative for the JC virus have a much lower risk of developing PML.

  • Before taking this medication, let your healthcare team know about other medical conditions that you may have or other medications (even over-the-counter medications or complementary therapies) you may be taking.

  • The best way to control your disease is by taking your medication as directed. Even when you do not have any symptoms, it is very important to continue taking your medication to prevent your disease from becoming active again. Do not alter the amount of the medication or how frequently you take it on your own.

  • If you have any side effects or you continue to have symptoms, speak to your healthcare team immediately.

For further information, please check out or follow this link:

PDF /sites/default/files/2022-10/Biologics%2010.2022_1.pdf